House Health reform Bill: GOP Moves

11 March 1996

At the request of US house Speaker Newt Gingrich, deputy chief whip Dennis Hastert is coordinating different versions of bills to deal with gaps in health insurance cover, to coordinate them into a bill similar to the Senate's bipartisan Kassebaum-Kennedy bill. But, says Rep Hastert, the Republicans are planning extra provisions on malpractice and anti-trust law so "health care providers can get together, share facilities and hold down costs," plus medical savings accounts and health insurance tax deductions for the self-employed, and to have the bill out of the House by end-March.

It is felt these extra provisions will harm the bill's chances of getting through Congress in a form acceptable to the President, who endorsed the basic bill in his January State of the Union message. Rep Hastert denied Democratic claims that the GOP wants to sabotage the bill. Health insurance lobbyists who met with Rep Hastert support the Kassebaum-Kennedy bill in part because they see it as a way to boost confidence in the private insurance system. As an incremental and reasonable step to provide coverage for the uninsured, they feel it should not have amendments that would jeopardize its passage.

many Republicans want tax incentives for medical savings accounts, and no bill will get out of the House without this, said a Hastert aide. House Republicans also want allowable tax deductions for amounts paid by the self-employed for health insurance raised to 50% from 30%; the budget bill vetoed by the President in December contained such a provision.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight